Interventional Radiology Imaging

What Imaging Is Needed for Initial Staging of Asymptomatic Chronic Lymphocytic Leukemia?

·
What Imaging Is Needed for Initial Staging of Asymptomatic Chronic Lymphocytic Leukemia?

A 72-year-old man presents to your office for follow-up after routine blood work showed a persistent, isolated lymphocytosis. Flow cytometry confirms a diagnosis of chronic lymphocytic leukemia (CLL). On examination, he has no palpable lymphadenopathy or hepatosplenomegaly and reports no fevers, night sweats, or weight loss. He is entirely asymptomatic. You are now faced with the decision of initial staging. While clinical staging systems like Rai and Binet are paramount, you consider whether cross-sectional imaging is necessary to establish a baseline and assess for occult bulky disease. This article details the clinical workflow for this specific scenario, explaining why the American College of Radiology (ACR) rates CT of the chest, abdomen, and pelvis with IV contrast as ‘May be appropriate (Disagreement)’, reflecting a key nuance in modern CLL management.

Who Fits This Clinical Scenario?

This guidance applies specifically to adults with a new diagnosis of chronic lymphocytic leukemia (CLL) who are asymptomatic at presentation. The key inclusion criteria are a confirmed diagnosis via hematopathology and the absence of constitutional “B” symptoms (unexplained fever, drenching night sweats, significant unintentional weight loss) or symptoms related to bulky disease or cytopenias.

It is critical to distinguish this scenario from others that require a different imaging approach. This workflow does not apply to:

  • Symptomatic Patients: Adults with CLL who present with B symptoms, palpable bulky lymphadenopathy, or symptomatic splenomegaly. These findings often trigger an evaluation for treatment and may warrant a different imaging rationale.
  • Patients with Suspected Richter’s Transformation: Individuals with a sudden change in clinical status, such as rapidly growing lymph nodes, worsening B symptoms, or rising lactate dehydrogenase (LDH), require an expedited workup, often involving FDG-PET/CT.
  • Other Leukemias: This guidance is specific to CLL. The initial staging for acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), or chronic myeloid leukemia (CML) follows distinct pathways.
  • Pediatric Patients: The evaluation and management of leukemia in children are fundamentally different and are not covered here.

What Diagnoses Are You Working Up in This Scenario?

In an asymptomatic patient with a new CLL diagnosis, imaging is not for diagnosis but for staging and prognostication. The primary goal is to anatomically quantify the extent of disease, which complements the clinical and laboratory-based staging systems. The key findings you are assessing for on the initial scan serve as a critical baseline for all future follow-up.

Extent of Lymphadenopathy: CLL is characterized by the accumulation of neoplastic lymphocytes in lymph nodes. While a physical exam can detect superficial adenopathy, cross-sectional imaging is required to evaluate deep, non-palpable nodes in the mediastinum, retroperitoneum, and pelvis. The presence of “bulky” disease, often defined as a nodal mass greater than 5 cm or 10 cm, is an important prognostic factor that may influence future treatment decisions.

Organomegaly (Splenomegaly and Hepatomegaly): The spleen and liver are common sites of leukemic infiltration. Imaging provides a precise, objective measurement of organ size, which is a component of both the Rai and Binet staging systems. Significant splenomegaly can be a harbinger of future symptoms and cytopenias.

Occult Richter’s Transformation: Although uncommon in a truly asymptomatic patient, an initial staging CT can occasionally reveal findings suggestive of transformation to a high-grade lymphoma. A single, dominant, rapidly growing, or necrotic nodal mass amidst a background of smaller nodes is a red flag that would prompt an immediate biopsy, fundamentally altering the patient’s prognosis and management plan.

Why Is CT of the Chest, Abdomen, and Pelvis Considered for Staging Asymptomatic CLL?

For an asymptomatic adult at initial CLL staging, the ACR Appropriateness Criteria panel rates CT chest abdomen pelvis with IV contrast as May be appropriate (Disagreement). This rating reflects the ongoing clinical debate about the utility of routine imaging in this specific population.

The rationale for performing the CT is to establish a comprehensive anatomic baseline. It accurately delineates the full extent of lymphadenopathy and measures organ size, providing objective data that physical exam alone cannot. Discovering bulky disease can impact prognosis and provides a crucial reference point to assess disease progression over time. If the patient later develops symptoms, having this baseline scan is invaluable for determining the pace of change.

The “Disagreement” in the rating stems from the fact that for many patients with early-stage, low-burden disease, the imaging results will not change the immediate management, which is typically observation or “watch and wait.” In these cases, some clinicians argue that the radiation exposure (☢☢☢☢ 10-30 mSv) and potential for incidental findings may outweigh the benefits. The decision to image should therefore be individualized, based on a discussion with the patient and the managing hematologist.

When considering alternatives, their limitations for this specific scenario become clear:

  • FDG-PET/CT is also rated May be appropriate (Disagreement). While it is the study of choice for suspected Richter’s transformation due to the high metabolic activity of aggressive lymphomas, it is not typically necessary for routine initial staging in an asymptomatic patient. Its higher radiation dose and cost make it less suitable for baseline screening without a specific clinical concern for transformation.
  • Radiography chest is rated Usually not appropriate. A chest X-ray is insensitive for assessing mediastinal adenopathy and provides no information about the abdomen or pelvis, where the bulk of disease is often located. It is inadequate for comprehensive staging.

If a CT is ordered, it should be performed with IV contrast to optimally visualize lymph nodes, delineate them from adjacent vessels, and evaluate the solid organs. Once you’ve decided on CT chest abdomen pelvis with IV contrast, our protocol guide covers the technique, contrast, and reading principles: CT Chest/Abdomen/Pelvis with IV Contrast.

What’s Next After CT? Downstream Workflow

The results of the initial staging CT will guide the subsequent management strategy and follow-up schedule. The downstream workflow depends on the findings, which establish the patient’s anatomic disease burden.

  • If the CT shows minimal disease (e.g., only scattered small lymph nodes, no significant organomegaly), it confirms a low disease burden. This finding strongly supports a “watch and wait” approach. The scan serves as a valuable baseline for future comparison, but no immediate action is needed. Follow-up will be guided by clinical status and blood counts.
  • If the CT reveals bulky disease (e.g., nodal conglomerates >5-10 cm) or massive splenomegaly, this information has significant prognostic value. Even if the patient is asymptomatic, the presence of bulky disease may place them in a higher-risk category and could lead to more frequent monitoring or consideration for earlier entry into a clinical trial.
  • If the CT is negative or shows low-burden disease, but the patient later develops symptoms (e.g., B symptoms, cytopenias), a repeat scan can be performed. Comparing the new scan to the initial baseline allows for objective quantification of disease progression, which is a key criterion for initiating therapy.
  • If the CT shows an indeterminate or suspicious finding (e.g., a single dominant or necrotic node), this raises concern for Richter’s transformation. The next step is not simply more imaging but a targeted intervention. This would typically involve a discussion with hematology and interventional radiology or surgery to plan for a biopsy of the suspicious lesion. An FDG-PET/CT may be ordered at this stage to confirm metabolic activity and guide the biopsy to the most active site.

Pitfalls to Avoid (and When to Get Help)

Navigating the initial staging of asymptomatic CLL requires careful clinical judgment. Here are several common pitfalls to avoid:

  • Routine Imaging for All Patients: Avoid a reflexive order for CT in every new CLL diagnosis. The decision should be individualized, as many low-risk patients will not benefit from immediate imaging.
  • Using the Wrong Modality: Do not order a chest radiograph for staging, as it is insufficient. Similarly, avoid ordering a PET/CT for routine baseline staging unless there is a specific clinical suspicion for Richter’s transformation.
  • Ordering Without Contrast: A non-contrast CT significantly limits the evaluation of lymph nodes and abdominal organs. Unless there is a severe contraindication, IV contrast is necessary for accurate staging.
  • Ignoring the Baseline Value: Do not dismiss a “negative” or “low-burden” scan as unhelpful. Its primary value is as a comparator for all future imaging, establishing a crucial reference point for disease trajectory.

If a patient develops new, rapidly progressive symptoms or if the CT shows a finding suspicious for transformation, this is a critical juncture that requires immediate escalation and collaborative discussion with the primary hematology/oncology team.

Related ACR Topics and Tools

This article is a deep dive into one specific clinical scenario. For a comprehensive overview of imaging across all presentations of leukemia, from initial staging to follow-up and post-therapy evaluation, please see our parent guide. It provides a broader context for the full spectrum of ACR recommendations.

Frequently Asked Questions

Why is imaging even considered for asymptomatic CLL if staging is primarily clinical?

While clinical staging systems (Rai/Binet) based on physical exam and blood counts are primary, cross-sectional imaging provides a more precise and objective assessment of the total disease burden. It can detect non-palpable deep lymphadenopathy and accurately measure organ size. Discovering bulky disease (>5-10 cm) has prognostic significance and establishes a critical baseline for monitoring future disease progression.

If both CT and PET/CT are rated ‘May be appropriate’, how do I choose between them?

The choice depends on the clinical question. For routine initial staging in an asymptomatic patient, a contrast-enhanced CT is generally sufficient to establish an anatomic baseline. An FDG-PET/CT is typically reserved for situations where there is a clinical suspicion of Richter’s transformation (e.g., B symptoms, rapidly growing nodes, high LDH), as it assesses the metabolic activity of the disease, which is high in aggressive lymphomas.

What does the ACR rating ‘May be appropriate (Disagreement)’ actually mean for my practice?

This rating signifies that there is clinical equipoise and a lack of consensus among experts regarding the routine use of this imaging test for this specific scenario. It means that ordering a CT may be reasonable, but it is not considered mandatory for all patients. The decision should be individualized based on discussion with the patient and the managing hematologist, weighing the benefit of establishing a baseline against the costs and radiation exposure.

Does a ‘negative’ or ‘low-burden’ CT scan mean the patient doesn’t need follow-up?

No. A low-burden scan is a favorable prognostic indicator and supports a ‘watch and wait’ strategy, but it does not eliminate the need for regular clinical and laboratory follow-up. CLL is a chronic condition, and the scan’s primary value is as a baseline. The patient’s disease can still progress, and follow-up is essential to monitor for clinical or hematologic changes that would warrant a change in management.

Is an MRI a reasonable alternative to CT for staging CLL?

According to the ACR Appropriateness Criteria, various MRI protocols for the chest, abdomen, and pelvis are rated ‘Usually not appropriate’ for this scenario. While MRI avoids ionizing radiation, it is generally slower, more expensive, and can be less sensitive for detecting small-volume pulmonary or diffuse disease compared to CT. CT remains the preferred modality for cross-sectional anatomic staging of lymphoma and leukemia.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026